H. Lundbeck A/S Release: Brintellix® Demonstrated A Statistically Significantly Superior Improvement Compared To Escitalopram In Improving Sexual Functioning In Well Treated Patients Suffering From Depression And Experiencing Treatment-Emergent Sexual Dys

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Valby, 2014-06-17 15:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) today will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs. escitalopram in patients with well treated Major Depressive Disorder (MDD, commonly referred to as “depression”) experiencing treatment-emergent sexual dysfunction (TESD). The data, accepted as a late-breaker, will be shared in a poster presentation (#41) today at 11:15 a.m. EDT.

Help employers find you! Check out all the jobs and post your resume.

Back to news